Literature DB >> 22565944

Stromedix acquisition signals growing interest in fibrosis.

Malorye Allison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22565944     DOI： 10.1038/nbt0512-375

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.

Authors:  James Adams; Edward C Anderson; Emma E Blackham; Yin Wa Ryan Chiu; Thomas Clarke; Natasha Eccles; Luke A Gill; Joshua J Haye; Harvey T Haywood; Christian R Hoenig; Marius Kausas; Joelle Le; Hannah L Russell; Christopher Smedley; William J Tipping; Tom Tongue; Charlotte C Wood; Jason Yeung; James E Rowedder; M Jonathan Fray; Thomas McInally; Simon J F Macdonald
Journal:  ACS Med Chem Lett       Date:  2014-09-19       Impact factor: 4.345

Review 2.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

Review 3.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

Review 4.  Matrix control of transforming growth factor-β function.

Authors:  Masahito Horiguchi; Mitsuhiko Ota; Daniel B Rifkin
Journal:  J Biochem       Date:  2012-08-24       Impact factor: 3.387

5.  LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis.

Authors:  Mitsuko Hara; Akiko Kirita; Wakako Kondo; Tomokazu Matsuura; Keisuke Nagatsuma; Naoshi Dohmae; Shinji Ogawa; Shinobu Imajoh-Ohmi; Scott L Friedman; Daniel B Rifkin; Soichi Kojima
Journal:  Springerplus       Date:  2014-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.